Magazine article Clinical Psychiatry News

Atypical Quetiapine Appears Effective for Bipolar Depression

Magazine article Clinical Psychiatry News

Atypical Quetiapine Appears Effective for Bipolar Depression

Article excerpt

SAN DIEGO -- The atypical antipsychotic quetiapine led to significantly greater reductions in bipolar depression than did placebo within the first week of treatment and throughout an 8-week randomized, controlled study of 511 patients. Andrew J. Cutler, M.D., said.

Data from the large trial will be published in the American Journal of Psychiatry, he said at a psychopharmacology congress sponsored by the Neuroscience Education Institute.

Patients were randomized to once-nightly doses of placebo, 300 mg of quetiapine (Seroquel), or 600 mg of quetiapine. After 1 week of treatment, mean Hamilton Depression Rating Scale scores decreased by about 5 points in the placebo group and by about 8 points in each quetiapine group, compared with baseline. After 8 weeks, scores had dropped 8-9 points in the placebo group and 13-14 points in the quetiapine groups, compared with baseline.

The differences between the placebo group and each quetiapine group were significant at each weekly assessment, said Dr. Cutler of the University of South Florida. Tampa. He is a speaker and consultant for, and has received research grants from, the company that makes quetiapine: AstraZeneca. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.